He has made significant contributions to the field of pharmacogenomics including the identification of a gene that is involved in cardiomyopathy and congestive heart failure after cancer treatment (Aminkeng F et al, Nature Genetics. 2015 Sep; 47(9):1079-84.). He is the recipient of a number of fellowships including the Canadian Institutes of Health Research, Michael Smith Foundation for Health Research and the British Columbia Children Hospital Research Institute Bertram Hoffmeister Postdoctoral Fellowships. He has also been recognized for a distinguish academic and scientific career through a number of career awards including the Canadian Society of Pharmacology and Therapeutics Boehringer Ingelheim Postdoctoral Award in Pharmacology, the British Columbia Children Hospital Research Institute award for outstanding achievement by a postdoctoral fellow, the Golden Helix Top Prize and the Canadian Society of Pharmacology and Therapeutics Publication Award. He currently serves on the Editorial Board of the Journal of Population Therapeutics and Clinical Pharmacology and is a member of the Canadian Society of Pharmacology and Therapeutics Scientific Program Committee.
Instructor in Medicine, Harvard Medical School
Associate Physician, Brigham and Women's Hospital
The primary focus of Dr Tantisira's research efforts, have been in the pharmacogenetics of asthma therapeutics. With a focus on the pharmacogenetics of the beta-agonist and corticosteroid pathways and have made significant progress, they have identified genes that influence bronchodilator response in asthmatics, corticosteroid response over time as manifested by changes in FEV1, differences in airways hyperresponsiveness in patients on corticosteroids, and prediction of who will be hospitalized while on inhaled steroids
PGRN Hub & the Featured Investigator